【摘要】：目的研究早期宮頸惡性腫瘤、宮頸良性腫瘤和健康人群P16自身抗體表達(dá)情況。方法利用自行設(shè)計(jì)的P16表位多肽片段作為包被抗原,采用改良Eli SA方法檢測141例宮頸癌患者、133例宮頸良性腫瘤患者和148例健康志愿者血漿中P16自身抗體的表達(dá)情況。結(jié)果惡性腫瘤組P16自身抗體表達(dá)水平顯著高于健康對照組(t=4.016,P0.001)和良性腫瘤組(t=3.879,P0.001)。Ⅰ期宮頸癌組和Ⅱ期宮頸癌組P16表達(dá)水平明顯高于健康人群(t=7.800,P0.001;t=5.198,P0.001)及良性腫瘤組(t=4.466,P0.001;t=2.288,P0.001),且Ⅰ期宮頸癌組與Ⅱ期宮頸癌組P16自身抗體表達(dá)水平存在差異(t=2.012,P0.05)。宮頸癌組特異度為90%時(shí),敏感度15.6%,曲線下面積為0.652。Ⅰ期宮頸癌組抗P16的Ig G自身抗體特異度為90%時(shí),敏感度達(dá)到了20.3%,曲線下面積為0.719。結(jié)論 P16作為一種腫瘤相關(guān)抗原,其自身抗體可以反映出宮頸病變的連續(xù)發(fā)展變化,可能是早期診斷宮頸病變的一種潛在血清學(xué)標(biāo)志物。
[Abstract]:Objective to study the expression of P16 autoantibodies in early cervical malignancies, benign cervical neoplasms and healthy people. Methods the expression of P16 autoantibodies in plasma of 141 patients with cervical cancer, 133 patients with benign cervical tumor and 148 healthy volunteers was detected by modified Eli SA method. Results the expression level of P16 autoantibody in malignant tumor group was significantly higher than that in healthy control group (t = 4.016) and benign tumor group (t = 3.879). P0.001. The expression of P16 in patients with stage 鈪，

本文編號：2301575